看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Ps Multiple | 2.1x - 2.3x | 2.2x |
| Selected Fwd Ps Multiple | 2.0x - 2.2x | 2.1x |
| Fair Value | €34.36 - €37.98 | €36.17 |
| Upside | 35.2% - 49.5% | 42.3% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| Bristol-Myers Squibb Company | - | NYSE:BMY |
| Novartis AG | - | OTCPK:NVSE.F |
| Bayer Aktiengesellschaft | - | OTCPK:BAYZ.F |
| Merck KGaA | - | OTCPK:MKGA.F |
| H. Lundbeck A/S | - | CPSE:HLUNA |
| Eisai Co., Ltd. | - | DB:EII |
| Select Price / LTM Sales Ratio | ||||||||
| Benchmark Companies | ||||||||
| BMY | NVSE.F | BAYZ.F | MKGA.F | HLUN A | EII | |||
| NYSE:BMY | OTCPK:NVSE.F | OTCPK:BAYZ.F | OTCPK:MKGA.F | CPSE:HLUNA | DB:EII | |||
| Historical Sales Growth | ||||||||
| 5Y CAGR | 13.1% | 1.2% | 1.4% | 5.5% | 5.3% | 2.6% | ||
| 3Y CAGR | 1.4% | 5.6% | 1.9% | 2.4% | 10.5% | 1.4% | ||
| Latest Twelve Months | 2.6% | 12.9% | -2.0% | 1.7% | 13.9% | 9.4% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 2.1% | 27.4% | -4.0% | 13.8% | 10.7% | 7.2% | ||
| Prior Fiscal Year | 17.8% | 18.4% | -6.2% | 13.5% | 11.5% | 5.7% | ||
| Latest Fiscal Year | -18.5% | 23.1% | -5.5% | 13.1% | 14.3% | 5.9% | ||
| Latest Twelve Months | 10.6% | 24.7% | -7.4% | 13.2% | 14.3% | 6.3% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 6.8x | 10.8x | 9.2x | 9.0x | 7.0x | 12.0x | ||
| Price / LTM Sales | 2.0x | 4.1x | 0.5x | 2.2x | 1.5x | 1.5x | ||
| LTM P/E Ratio | 18.7x | 16.8x | -7.4x | 16.4x | 10.2x | 24.6x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/S Ratio | 0.5x | 2.0x | 4.1x | |||||
| Historical LTM P/S Ratio | 1.5x | 2.4x | 3.0x | |||||
| Selected Price / Sales Multiple | 2.1x | 2.2x | 2.3x | |||||
| (x) LTM Sales | 803,022 | 803,022 | 803,022 | |||||
| (=) Equity Value | 1,651,354 | 1,738,267 | 1,825,181 | |||||
| (/) Shares Outstanding | 281.9 | 281.9 | 281.9 | |||||
| Implied Value Range | 5,858.20 | 6,166.53 | 6,474.85 | |||||
| FX Rate: JPY/EUR | 172.7 | 172.7 | 172.7 | Market Price | ||||
| Implied Value Range (Trading Cur) | 33.93 | 35.71 | 37.50 | 25.41 | ||||
| Upside / (Downside) | 33.5% | 40.5% | 47.6% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | BMY | NVSE.F | BAYZ.F | MKGA.F | HLUN A | EII | |
| Value of Common Equity | 93,488 | 223,591 | 25,065 | 47,061 | 34,845 | 1,236,815 | |
| (/) Shares Outstanding | 2,035.4 | 1,935.9 | 982.4 | 434.8 | 1,179.2 | 281.9 | |
| Implied Stock Price | 45.93 | 115.50 | 25.51 | 108.24 | 29.55 | 4,387.62 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 0.86 | 0.86 | 1.00 | 172.67 | |
| Implied Stock Price (Trading Cur) | 45.93 | 115.50 | 29.81 | 126.45 | 29.55 | 25.41 | |
| Trading Currency | USD | USD | USD | USD | DKK | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 0.86 | 0.86 | 1.00 | 172.67 | |